Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 Aug 12;12(15):1438-1447.
doi: 10.1016/j.jcin.2019.04.038.

Long-Term Outcomes of the FORMA Transcatheter Tricuspid Valve Repair System for the Treatment of Severe Tricuspid Regurgitation: Insights From the First-in-Human Experience

Lluis Asmarats  1 , Gidon Perlman  2 , Fabien Praz  3 , Mark Hensey  4 , Michael P Chrissoheris  5 , Francois Philippon  1 , Hadass Ofek  4 , Jian Ye  4 , Rishi Puri  6 , Philippe Pibarot  1 , Adrian Attinger  4 , Robert Moss  4 , Elisabeth Bédard  1 , Aris Moschovitis  3 , David Reineke  3 , Sandra Lauck  4 , Philipp Blanke  4 , Jonathon Leipsic  4 , Konstantinos Spargias  5 , Stephan Windecker  3 , John G Webb  4 , Josep Rodés-Cabau  7
Affiliations
Free article
Multicenter Study

Long-Term Outcomes of the FORMA Transcatheter Tricuspid Valve Repair System for the Treatment of Severe Tricuspid Regurgitation: Insights From the First-in-Human Experience

Lluis Asmarats et al. JACC Cardiovasc Interv. .
Free article

Abstract

Objectives: To evaluate the long-term (≥2 years) outcomes following transcatheter tricuspid valve repair (TTVr) with the FORMA Transcatheter Tricuspid Valve Repair System (Edwards Lifesciences, Irvine, California).

Background: Scarce data exist on long-term outcomes following TTVr.

Methods: This multicenter experience included patients with severe tricuspid regurgitation (TR) who underwent TTVr with the FORMA system at 4 centers under a compassionate clinical use program. Data were collected at baseline, 30 days, and 1 year, and yearly thereafter.

Results: Nineteen patients (76 ± 9 years of age, 74% women, mean EuroSCORE II [European System for Cardiac Operative Risk Evaluation] 9.2 ± 5.6%) with functional TR were included. Procedural success was achieved in 17 (89%) patients and there were no cases of 30-day mortality. At a median follow-up of 32 (interquartile range: 24 to 36) months, 4 (24%) patients had died (3 from terminal heart failure, 1 from sepsis) and 3 (18%) patients required rehospitalization for heart failure. There was 1 device-related thrombosis and 1 pulmonary embolism, both in the setting of subtherapeutic oral anticoagulation. Less than severe TR was observed at echocardiography in 67% of patients at the 2- to 3-year follow-up. Among 15 successfully implanted patients with at least 24-month follow-up, significant improvements in New York Heart Association functional class (p < 0.001), 6-min walk test (+54 m; p = 0.016) and Kansas City Cardiomyopathy Questionnaire score (+16 points; p = 0.016) were observed, compared with baseline.

Conclusions: TTVr using the FORMA system showed favorable long-term safety profile in high-surgical-risk patients, with sustained functional improvement and acceptable TR reduction up to 3 years.

Keywords: transcatheter coaptation system; transcatheter tricuspid valve intervention; tricuspid regurgitation.

PubMed Disclaimer

Comment in

Publication types

MeSH terms